A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this post marketing study is to determine the plasma concentration of
bortezomib (unchanged drug) to assess the pharmacokinetic (PK - the study of the way a drug
enters and leaves the blood and tissues over time) properties in the Taiwanese population. It
will also provide expanded access (expanded access, sometimes called "compassionate use," is
the use of an investigational drug outside of a clinical trial to treat a participant with a
serious or immediately life-threatening disease or condition who has no comparable or
satisfactory alternative treatment options) to bortezomib for the same group of participants
with multiple myeloma (cancer of the types of cells normally found in bone marrow).